Cara Therapeutics, Inc.
NASDAQ:CARA
0.4226 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 20.968 | 41.867 | 23.028 | 135.082 | 19.886 | 13.469 | 0.911 | 0.086 | 3.803 | 3.177 | 11.964 | 1.19 | 0 |
| Cost of Revenue
| 6.174 | 7.266 | 1.554 | 107.07 | 113.164 | 75.531 | 48.524 | 49.253 | 21.221 | 15.068 | 8.685 | 1.921 | 0 |
| Gross Profit
| 14.794 | 34.601 | 21.474 | 28.012 | -93.278 | -62.062 | -47.613 | -49.167 | -17.418 | -11.891 | 3.279 | -0.731 | 0 |
| Gross Profit Ratio
| 0.706 | 0.826 | 0.933 | 0.207 | -4.691 | -4.608 | -52.265 | -571.709 | -4.58 | -3.743 | 0.274 | -0.614 | 0 |
| Reseach & Development Expenses
| 108.51 | 91.879 | 82.701 | 107.851 | 113.82 | 75.531 | 48.524 | 49.253 | 21.221 | 15.068 | 8.685 | 4.597 | 7.159 |
| General & Administrative Expenses
| 27.649 | 30.257 | 29.41 | 21.749 | 17.745 | 15.32 | 11.872 | 9.233 | 7.77 | 6.181 | 3.516 | 2.829 | 2.407 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 27.649 | 30.257 | 29.41 | 21.749 | 17.745 | 15.32 | 11.872 | 9.233 | 7.77 | 6.181 | 3.516 | 2.829 | 2.407 |
| Other Expenses
| 0 | 2.061 | 0.642 | 0.097 | 4.49 | 2.98 | 1.156 | 0.652 | 0.101 | 0.361 | 0 | 0 | -0.18 |
| Operating Expenses
| 136.289 | 122.136 | 112.111 | 129.697 | 131.565 | 90.851 | 60.396 | 58.486 | 28.991 | 21.249 | 12.201 | 7.426 | 9.566 |
| Operating Income
| -121.495 | -87.535 | -89.083 | 5.385 | -111.679 | -77.382 | -59.485 | -58.4 | -25.188 | -18.072 | -0.237 | -6.236 | -9.566 |
| Operating Income Ratio
| -5.794 | -2.091 | -3.868 | 0.04 | -5.616 | -5.745 | -65.296 | -679.07 | -6.623 | -5.688 | -0.02 | -5.24 | 0 |
| Total Other Income Expenses Net
| 2.982 | 2.061 | 0.642 | 2.334 | 4.49 | 2.98 | 1.156 | 0.652 | 0.101 | 0.126 | -3.756 | -0.066 | -0.275 |
| Income Before Tax
| -118.513 | -85.474 | -88.441 | 7.719 | -107.189 | -74.402 | -58.329 | -57.748 | -25.087 | -17.946 | -3.993 | -6.302 | -9.841 |
| Income Before Tax Ratio
| -5.652 | -2.042 | -3.841 | 0.057 | -5.39 | -5.524 | -64.027 | -671.488 | -6.597 | -5.649 | -0.334 | -5.296 | 0 |
| Income Tax Expense
| 0 | -2.061 | -0.248 | -0.691 | -0.816 | -0.389 | -0.204 | -0.468 | -0.397 | -0.201 | -0.03 | -0.031 | -0.035 |
| Net Income
| -118.513 | -83.413 | -88.193 | 8.41 | -106.373 | -74.013 | -58.125 | -57.28 | -24.69 | -17.745 | -3.963 | -6.271 | -9.806 |
| Net Income Ratio
| -5.652 | -1.992 | -3.83 | 0.062 | -5.349 | -5.495 | -63.804 | -666.047 | -6.492 | -5.585 | -0.331 | -5.27 | 0 |
| EPS
| -2.19 | -1.55 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.1 | -1 | -0.85 | -0.18 | -1.01 | -1.59 |
| EPS Diluted
| -2.19 | -1.55 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.1 | -1 | -0.85 | -0.18 | -1.01 | -1.59 |
| EBITDA
| -117.65 | -83.804 | -88.193 | 5.594 | -111.481 | -77.012 | -58.99 | -56.935 | -24.349 | -17.289 | 0.552 | -5.215 | -8.576 |
| EBITDA Ratio
| -5.611 | -2.091 | -3.868 | 0.041 | -5.616 | -5.745 | -65.296 | -679.07 | -6.623 | -5.688 | -0.02 | -4.382 | 0 |